StockData
Regencell Bioscience Holdings Ltd logo

Regencell Bioscience Holdings Ltd (RGC) company profile

RGCNasdaqMedicinal Chemicals & Botanical Products
Số liệu tài chính tới năm tài chính 2026, năm kết thúc ngày Jun 30, 2026Last filing: 20-F on Oct 7, 2026Score 5/30
$4.69+0.14 (+3.08%)

Close on Nov 18, 2026Market cap $2.33BP/E –Yield –

About Regencell Bioscience

Medicinal Chemicals & Botanical Products, SIC 2833

Regencell Bioscience Holdings Limited is an early-stage bioscience firm that researches, develops, and commercializes traditional Chinese medicine (TCM) formulas. The company focuses on formulas designed to treat neurocognitive disorders and degeneration, particularly attention deficit hyperactivity disorder (ADHD) and autism spectrum disorder (ASD). It operates primarily through its subsidiary, Regencell Bioscience Limited, in partnership with an experienced practitioner to develop standardized liquid-based formulations. The target patient population and end customers consist of individuals diagnosed with ADHD and ASD, along with their families and caregivers seeking alternative or holistic treatment options.

The company maintains its principal executive offices in Causeway Bay, Hong Kong, and holds corporate registration in the Cayman Islands. Its operations and clinical research activities are based primarily in Hong Kong, where it conducts efficacy trials with enrolled pediatric patients and collaborates with local practitioners. In addition to its active research entity, the organization maintains wholly owned corporate subsidiaries incorporated in Hong Kong and the British Virgin Islands for future operational needs.

Summary of the business section of Regencell Bioscience's latest annual report, written by StockData.

Company profile

Company

Legal name
Regencell Bioscience Holdings Ltd
Founded
2014
Headquarters
Hong Kong, China
Address
9/F Chinachem Leighton Plaza, 29 Leighton Road, Causeway Bay
Phone
852 2155 0823
Employees
13, Jun 30, 2021
Industry
Medicinal Chemicals & Botanical Products
Incorporated in
E9
Auditor
HTL International, LLC, Houston, Texas

Stock & identifiers

Ticker
RGC
Exchange
Nasdaq
IPO date
Jul 20, 2021
Shares outstanding
496M, Jun 30, 2026
Filer category
Large accelerated filer
Stock splits
38-for-1, Oct 31, 2025; 38-for-1, Jun 16, 2025
SEC CIK
1829667
CUSIP
G7487R100
FIGI
BBG00ZS40360
Share class FIGI
BBG00ZS40379
EIN
00-0000000

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Yat-Gai AuChief Executive Officer, Director437,896,116
James Wai Hong ChungCOO and Chief Strategy Officer, Director–
Ho Yau ChanFinancial Controller–
Yat-Pui AuChief Business Officer581,514
William Wing Yan Dr LoDirector485,629
Evana Yee Wah HuiDirector–
Margaret Hoor Han LoDirector604,050

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Jul 20, 2021
Offer price
$9.50
Exchange
Nasdaq
First trading day
Jul 19, 2021
First-day close
$9.56+0.6%
Lock-up ends (est.)
Jan 15, 2022

“Per Share Total Public offering price $ 9.50 $ 21,850,000 Underwriter discount (1) $ 0.7125 $ 1,638,750 Proceeds to us, before expenses $ 8.7875 $ 20,211,250 (1) We have agreed to reimburse the underwriter for certain expenses.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Corporate history

Events identified from SEC filings

See a number that looks wrong?